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Cancer cells frequently exploit the IGF signaling, a fundamental pathway mediating devel-
opment, cell growth, and survival. As a consequence, several components of the IGF
signaling are deregulated in cancer and sustain cancer progression. However, specific tar-
geting of IGF-IR in humans has resulted efficacious only in small subsets of cancers, making
researches wondering whether IGF system targeting is still worth pursuing in the clinical
setting. Although no definite answer is yet available, it has become increasingly clear that
other components of the IGF signaling pathway, such as IR-A, may substitute for the lack
of IGF-IR, and induce cancer resistance and/or clonal selection. Moreover, accumulating
evidence now indicates that IGF signaling is a central player in the induction/maintenance
of epithelial mesenchymal transition (EMT) and cell stemness, two strictly related pro-
grams, which play a key role in metastatic spread and resistance to cancer treatments.
Here we review the evidences indicating that IGF signaling enhances the expression of
transcription factors implicated in the EMT program and has extensive cross-talk with spe-
cific pathways involved in cell pluripotency and stemness maintenance. In turn, EMT and
cell stemness activate positive feed-back mechanisms causing up-regulation of various IGF
signaling components. These findings may have novel translational implications.
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INTRODUCTION
The IGF system exerts a fundamental role in the regulation of
growth, development, and metabolism in response to nutrients.
However, several lines of evidence have now well established that
this complex signaling network is also exploited by cancer cells
to sustain their growth and resistance to apoptosis. The IGF sys-
tem comprises two homologous receptors, the insulin and the
IGF-I receptor (IR and IGF-IR) and a third unrelated receptor,
the mannose 6-phosphate receptor (M6P/IGF-IIR), four secreted
molecules (insulin, IGF-I, IGF-II, proinsulin) characterized by var-
ious binding affinity to these receptors, and six binding proteins
(IGF-BPs) (1, 2). Differential splicing of IR gene produces two
IR isoforms that differ for the exclusion (IR-A) or the inclusion
(IR-B) of a small exon (exon 11) that encodes a stretch of 12
aminoacids located at the carboxyterminus of the IR α-subunit.
These two isoforms bind insulin with similar affinity, but differ
mainly for their binding affinity to IGF-II and proinsulin, which
is high for IR-A, but very low for IR-B (3, 4). Upon ligand bind-
ing, IR and/or IGF-IR become phosphorylated on several tyro-
sine residues coupled to specific intracellular signaling pathways,
including the Ras/Raf/MAPK and the PI3K signaling cascades.
In contrast, the M6P/IGF-IIR binds only IGF-II, and targets it
to lysosomal degradation, thus counteracting IGF-II mitogenic
effects (5).
Indeed, most malignancies show IR and IGF-IR overexpres-
sion together with loss of M6P/IGF-IIR, increased expression of
autocrine and/or paracrine IGF-I and IGF-II, and dysregulated
IGF-BPs production (6, 7). In particular, IR-A overexpression and
increased IGF-II autocrine production have been recognized to
have a key role in the progression of several malignancies. The
IGF system and its signaling in physiology and disease have been
recently reviewed by several papers to which we refer for more
detailed information (3, 6, 8).
Because of the frequent dysregulation of the IGF system in
cancer, various components of this system have recently become
attractive targets for anticancer therapies. One of the main
approaches pursued has been IGF-IR targeting, on the basis of
IGF-IR prominent involvement in growth regulation and its scarce
contribution to glucose metabolism (9). Instead, targeting the IR
has been considered a less desirable option because of its major
involvement in glucose metabolism, and the potential derange-
ment of glucose metabolism arising from IR blockade. However, a
few clinical trials using IGF-IR blocking antibodies have recently
failed our expectations, as only a small number of malignancies
(Ewing’s sarcomas and a small subset of NSCLC lung tumors) have
shown significant objective response to these treatments (10).
New insights useful for targeting the IGF system may come
from evidences indicating that this system is involved in stem
cell biology, and that IGF system dysregulation may contribute
substantially to the growth/expansion of cancer stem-like cells.
In fact, accumulating evidence strongly suggests that malignant
tumors are driven and sustained by a subset of non-differentiated
cells with stem cell-like properties, such as self-renewal, tumori-
genicity, and multi-lineage differentiation abilities (11). According
to this model of tumorigenesis, the early step in tumor develop-
ment is the clonal expansion of initiating stem cell pool through
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the unbalance between self-renewal and differentiation capacities.
For this reason, it has been suggested that these cells and/or their
immediate progeny may be targets for transformation (12).
The most clinically relevant features of cancer stem cells (CSCs)
are the inherent radio/chemo-resistance and the capacity to metas-
tasize (13). Recent studies have linked these features with the
epithelial-to-mesenchymal transition (EMT), a process in which
adherent epithelial cells loose their epithelial characteristics and
acquire mesenchymal properties, including fibroblastoid mor-
phology, invasive and migratory potential, self-renewal capacity,
and specific gene-expression changes similar to those of stem cells
(14). Herein, we will review recent studies that have provided
increasing evidence that IGF signaling is crucial in the main-
tenance of stem-like phenotype of cancer cells by contributing
to regulate EMT, pluripotency, and self-renewal. This emerging
concept will undoubtedly stimulate renewed efforts aimed at co-
targeting the IGF system and other pathways that contribute to
CSCs biology.
IGF SIGNALING IN NORMAL AND CANCER STEM CELL
BIOLOGY
Nowadays, there is strong evidence in support of a role for IR/IGF-
IR dependent signals in the biology of normal progenitor/stem
cells (15–20). In fact, it has been shown that self-renewal, pluripo-
tency, survival, and expansion of human embryonic stem cells
require IGF-II produced by the supportive niche (15). Interest-
ingly, neural progenitor/stem cells have been found to express
both IGF-IR and IR-A, with a predominance of the latter, and
to be exquisitely sensitive to IGF-II for self-renewal. In contrast,
lineage restricted progenitors expressed preferentially the IGF-IR
and responded to IGF-I (21). An IGF-II analog that binds the IR-A
but not the M6P/IGF-IIR was still able to promote self-renewal of
neural stem cells also in the presence of blocking antibodies against
the IGF-IR, further reinforcing the concept that IGF-II promotes
stemness through the IR-A, and not through the M6P/IGF-IIR or
the IGF-IR (22).
Moreover, an important role of the IGF system has been recog-
nized in cancer progenitor/stem cells from solid and hematopoietic
malignancies. In this context, we have found that IR and IGF-IR,
as well as cognate ligands IGF-I and IGF-II, are overexpressed in
human thyroid progenitor/stem cells cultured as thyrospheres. IR-
A and IGF-II were especially predominant in thyrospheres from
cancer cells, where only IGF-II stimulated self-renewal ability.
However, both IGF-I and IGF-II were able to stimulate sphere
volume. IR-A and IGF-IR, as well as cognate ligands markedly
declined in differentiating cells (23). Similar findings have been
reported also in hepatocellular carcinoma, where IGF-IR and
IGF-II appear to be implicated in self-renewal ability of hepatic
CSCs (24).
Recently, it has been shown that IGF-IR expression and acti-
vation is greater in breast CSCs, as compared to normal breast
stem cells (25). IGF-IR knockdown or the specific inhibition of its
downstream signaling, was able to reduce the pool of breast CSCs,
their capacity to undergo the EMT process and to form mammos-
pheres in vitro and tumors in vivo. These data indicate that, in
breast cancer cells, IGF-IR may be considered as a marker of stem-
ness and a suitable therapeutic target. Similarly, high expression of
IGF-IR in lung adenocarcinoma cells was positively correlated with
the expression of CSC markers, while IGF-IR blockade inhibited
cell self-renewal and tumorigenicity in vivo (26).
Yet, chemoresistant colorectal cancer cells with CSC phenotype,
showed over-activated IGF-IR signaling, which was responsible
for enhanced sensitivity to IGF-IR-targeted therapy (27). Actually,
IGF-IR signaling appeared to enrich chemoresistant populations
of colon CSCs, which are selectively sensitive to the anti-IGF-
IR antibody figitumumab (28). In hepatocellular carcinoma cells,
resistance to the EGFR inhibitor gefitinib and cell stemness mark-
ers were found associated with increased IGF-IR nuclear transloca-
tion (29), a phenomenon recently described to occur in cancer cells
(30). Although the functional role of IGF-IR nuclear translocation
is still unclear, it seems to be involved in transcription enhance-
ment of certain genes, among which the IGF-IR gene itself, thus
promoting a feed-forward loop (31).
Recently, two groups have demonstrated that IGF-IR mediates
important growth/survival signals also in hematopoietic tumors.
Medyouf et al. reported that moderate levels of IGF-IR signaling
are sufficient for the expansion of bulk lymphoblastic leukemia
cell population (32). However, high levels of IGF-IR, and activa-
tion of its downstream signals are required for sustained growth of
human T acute lymphoblastic leukemia stem cells. Most intrigu-
ing, the same authors have shown that moderate inhibition of
IGF-IR signaling compromises leukemia-initiating cell activity
and their transplantability in syngeneic/congenic secondary recip-
ients. Others have shown that IGF-IR signaling contributes to the
malignant transformation of normal committed myeloid prog-
enitors, which were responsive to the growth inhibitory effect of
IGF-IR/IR selective tyrosine kinase inhibitors (33).
In summary, a growing body of evidence highlights the impor-
tance of IR-A and IGF-IR in regulating stem cell biology, and
supports the notion that IGF-I levels in the newborn are positively
related to the total number of stem cells, which is associated with
the risk of future cancers (19). These studies also raise the possi-
bility to explore IGF-IR specific pharmacological inhibition for a
variety of human malignancies, in order to sensitize chemore-
sistant stem-like cells to classical therapies and reduce relapse
rates.
A COMPLEX ROLE OF IGF SIGNALING IN EMT PROGRAM
THE EMT PROGRAM AND CANCER STEM CELLS
The EMT program regulates the transition of epithelial cancer cells
from an epithelial to a motile mesenchymal morphology. EMT has
an important role during embryogenesis and is highly conserved
in adult life to guarantee plasticity, tissue repair, and maintenance.
A key feature of EMT is the decreased expression of E-cadherin, a
transmembrane cell adhesion molecule important in maintaining
epithelial cellular polarity, along with increased expression of mes-
enchymal markers such as vimentin, fibronectin, and N-cadherin.
These changes drive the transformation of adhesive, non-motile
epithelial-like cells into motile, stem-like cells.
Although the origin of CSCs is controversial, recent observa-
tions support the notion that they may arise by the activation of the
EMT program, which is the first step for tumor metastatic dissemi-
nation. Indeed, by either overexpressing EMT-inducing transcrip-
tion factors, Snail or Twist, or by exposing the cells to TGFβ, it is
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possible to induce stemness features in non-tumorigenic human
mammary embryonic cells, as well as to increase tumorigenic-
ity in xenotransplants (14, 34). Furthermore, high expression of
EMT markers in colorectal, breast, and ovarian cancers correlates
with the de-repression of stemness gene signature, the develop-
ment of chemo-/radio-resistance, and the acquisition of metastatic
potential (34–36). These evidences strongly suggest that the EMT
process has a close relationship with CSCs and their metastatic
ability. A complex network of factors that includes growth factors,
cytokines, transcription factors, and the tumor microenvironment
tightly regulates the EMT process. The transcription factors con-
trolling EMT program belong to the ZEB, Snail, and Twist families.
These factors are tightly regulated at transcriptional, translational,
and epigenetic level, and act as molecular switches favoring the
induction of EMT. They recognize the E-box DNA sequences in
the promoter region of E-cadherin, recruit cofactors and the his-
tone deacetylase, and specific miRNAs, causing down-regulation
of E-cadherin expression. Deregulation of EMT-activating tran-
scription factors have been observed in several cancers. Snail has
been linked with tumor grade, metastasis, recurrence, and poor
prognosis (37). Snail and Twist further cooperate in inducing the
expression of ZEB1, which controls genes relevant in metasta-
sis and migration of CSCs also by repressing stemness-inhibiting
microRNAs (38). For their key role in endowing cancer cells with
stem-like properties and with aggressive pro-invasive phenotype,
these transcription factors have been suggested to be not only
attractive diagnostic and prognostic biomarkers but also potential
therapeutic targets.
IGF SIGNALING AND EMT PROGRAM: A STRICT RELATIONSHIP
Stimulation of the IGF axis in immortalized or in cancer cells
is now recognized to be able to induce up-regulation of several
transcription repressors involved in the EMT process. More than
one decade ago, IGF-I was shown to increase mRNA and protein
expression of Twist, not only in mouse fibroblasts overexpressing
the human IGF-IR, but also in mouse skeletal muscle, through the
activation of the MAPK pathway (39). Although this study was
carried out in non-transformed mesenchymal mouse cells, it is
noteworthy that IGF-I antiapoptotic effect was partially mediated
by Twist up-regulation.
Several studies have been conducted in malignant or immor-
talized epithelia cells. The MEK/ERK pathway was found also
involved in ZEB1 up-regulation by IGF-I (40). In ARCaPE prostate
cancer cells, which have an epithelial phenotype and low ZEB1
expression, IGF-I is expressed and secreted at low levels. When
cells were exposed to IGF-I, they showed increased ZEB1, N-
cadherin, and fibronectin, resembling the more mesenchymal cell
variant ARCaPM. ZEB1 blockade up-regulated E-cadherins and
suppressed cell motility and invasive potential (40). Although
ZEB1 activation was downstream the MEK/ERK pathway, inhi-
bition of this pathway was only partially able to revert the epithe-
lial phenotype, possibly because of the induction of irreversible
changes.
In addition to the MEK/ERK pathway, which is implicated in
Twist and ZEB1 up-regulation, GSK3β is now recognized as an
essential EMT regulator in response to IGFs. Initially identified
as an enzyme involved in the regulation of glycogen synthesis in
response to insulin, GSK3β is known to play a key role in the
canonical Wnt signaling by phosphorylating β-catenin and induc-
ing its proteasomal targeting and degradation (see below) (41,
42). In addition, GSK3β also regulates EMT in a more complex
way, which involves direct reduction of Snail and Slug expres-
sion (43). With regard to Snail, GSK3β is able to phosphorylate
it, causing proteasome dependent degradation (44). GSK3β also
represses Snail transcription via NF-kB activation (45). In lung
cancer, it was shown that GSK3β also phosphorylates Slug pro-
tein, causing its ubiquitination by the E3 ligase, carboxyl terminus
of Hsc70-interacting protein (CHIP), for proteasomal degrada-
tion (46). Inhibition of Akt reversed this phenotype, while inhi-
bition of GSK3β contributed to the mesenchymal phenotype.
Accordingly, Slug is required for metastatic spread of the trans-
formed melanoma cells (43), and GSK3β inhibition was associated
with increased Slug and N-cadherins expression and prevented
melanoma cells interaction with stromal cells and migration (47).
Normal epithelial cells have high basal GSK3β activity (48) and
express, therefore, low levels of Snail and Slug as a result of
decreased transcription and/or accelerated degradation of these
factors.
Both in normal and cancer cells, GSK3β inactivation, through
Ser9 phosphorylation, may occur by stimulation of the PI3K/Akt
and the MAPK pathways in response to several mitogens, includ-
ing insulin and paracrine/autocrine IGFs. However, in certain
cancers GSK3β may be also inactivated by the occurrence of mol-
ecular abnormalities, including the expression of constitutively
activated Akt3 and PTEN inactivation (49, 50). Several studies
addressing the relationship between IGF signaling and EMT have
been carried out in mammary cells. Early studies have shown that
breast cancer cells overexpressing IGF-IR acquire depolarization
and EMT phenotype following IGF-I stimulation (51). However,
also in non-transformed human breast cells MCF-10A, overex-
pression of a constitutively active IGF-IR induced EMT pheno-
type, anchorage-independent growth, invasion, and tumorigenesis
in vivo. Snail was markedly up-regulated, while no changes were
observed with regard to Slug, Twist, or ZEB1. Snail up-regulation
was dependent on NF-kB activation downstream IGF-IR. In fact,
all these changes were reverted by either NF-kB or IGF-IR block-
ade. Other studies have indicated that GSK3β inhibition by Akt
induces Snail and ZEB1/2 transcription via NF-kB (45, 52, 53),
and that NF-kB binds Snail promoter and increases its activity
(54). In addition, Akt induced NF-kB activation increases Snail
stability (55). IGF-I dependent induction of EMT phenotype in
MCF-10A cells required specific down-regulation of Akt1 together
with maintained Akt2 expression and increased ERK/MAPK sig-
naling (56). These studies highlight Akt isoform-specific effects on
EMT and migration in breast cells.
The insulin receptor substrate (IRS) proteins, which are key
effectors of both IR and IGF-IR, have also been involved in tumori-
genesis and in disruption of the normal epithelial phenotype in
mammary epithelial cells (57). In agreement with these findings,
it has been shown that MEMO1 (mediator of ErbB2-driven cell
motility 1) interacts with IRS-1 in a phospho-Tyr-dependent man-
ner and prevents IRS-1 dephosphorylation (58). As a consequence
of IRS-1 increased signaling, MCF-10A-IRS-1 and MCF-10A-
MEMO1 cells, showed cell scattering and loss of cell–cell contacts,
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FIGURE 1 | Schematic representation of IGF signaling involvement in
EMT. The two main signaling pathways downstream the IGF-IR are both
involved in the regulation of transcription factors of the Twist, Snail, and ZEB1
families, all involved in the EMT program. The IRS-1/PI3K/Akt pathway leads
to the phosphorylation and inactivation of GSK3β, thus preventing the
phosphorylation and proteasome targeting of Snail and Slug. The same
pathway also induces the activation of NF-kB transcription factor, which then
increases the transcription of Snail and ZEB1. On the other hand, the
Ras/Raf/ERK pathway is involved in the transcription of Twist and ZEB1. In
turn, Snail inhibits PTEN gene transcription, thus potentiating the
IRS-1/PI3K/Akt pathway. In addition, Slug increases the transcription of IGF-I,
the main IGF-IR ligand.
together with increase of N-cadherin and vimentin expression,and
down-regulation of the epithelial markers E-cadherin, occludin,
and β-catenin.
Interestingly, EMT may in turn trigger autocrine IGF-I pro-
duction, which activates a positive feed-back loop between IGF-IR
activation and SLUG expression, as shown in an in vitro model
of SLUG-induced EMT based on MCDK kidney fibroblasts (59).
Moreover, Snail suppresses PTEN expression, thus potentiating
the PI3K/Akt pathway (60).
Taken together, these findings indicate that the main IGF-IR
downstream pathways, the MAPK and the IRS/Akt/GSK3β cas-
cades, are potent inducers/activators of the transcription repres-
sors involved in EMT process. In turn, EMT process induces a
positive feed-back mechanism leading to increased IGF-IR sig-
naling through autocrine IGF-I production and reduced PTEN
activity. Figure 1 shows the relationship between the IGF system
and the EMT process.
IR-A OVEREXPRESSION, BOTH A CONSEQUENCE AND A CAUSE OF EMT
IR-A overexpression coupled with IGF-II autocrine production
may play an even more important role than IGF-IR overexpression
in mediating EMT. IR-A expression is physiologically enhanced
during prenatal life, and plays a major role to maximize IGF-II
and proinsulin biological effects (4, 61). In hepatoblastoma cell
lines, IR-A and IGF-II expression were positively correlated with
EMT and predicted sensitivity to the dual IGF-IR – IR inhibitor
OSI-906 (62). These data are reminiscent of similar data obtained
in thyroid cancer cells (63), showing that anaplastic cancer cells,
characterized by an EMT phenotype, express markedly elevated
levels of both IR-A and IGF-II, as compared with more differenti-
ated, papillary or follicular, thyroid cancer histotypes. Accordingly,
overactivation of the IR pathway has been recognized as a rele-
vant mechanism involved in resistance to IGF-IR blockade. In fact,
resistant Ewing’ sarcomas or breast cancers may show IR-A overex-
pression and enhanced activation by autocrine IGF-II production
(64, 65).
Several data suggest that IR-A favors a less differentiated phe-
notype while IR-B has the opposite effect. For instance, IR-A trans-
fection in HepG2 hepatoblastoma cells increased cell proliferation
and migration in response to IGFs and insulin, while transfection
with IR-B isoform decreased both biological effects (66). Similar
data were observed in colon cancer cells, where transfection with
IR-B decreased cell proliferation and increased biomarkers of dif-
ferentiation (67). In 32D cells transfection with IR-B, but not with
IR-A,was able to favor differentiation as measured by myeloperoxi-
dase expression (68). Additionally, mouse intestinal epithelial stem
cells and progenitors are characterized by high IR-A:IR-B ratio
(67). Noteworthy, activation of the insulin receptor contributes
to downregulate PTEN, representing an additional mechanism of
PI3K pathway activation (69).
Conversely, induction of differentiation in progenitor/stem
cells from human thyroid was associated with a dramatic decrease
in both absolute IR-A content and in IR-A:IR-B ratio, as well as
in reduction of autocrine IGF-II (23). HepG2 cells may also be
induced to differentiate and to assume a more typical epithelial
phenotype. These changes are associated with a marked decrease
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of IR-A:IR-B ratio from 80:20 to 20:80, confirming that a bidirec-
tional association exists between high IR-A:IR-B ratio and loss of
epithelial differentiation and EMT changes (66, 70).
These findings are highly consistent with the concept that,
although transcriptional regulation is required in driving EMT, a
coordinate program of alternative splicing is also important (71).
In fact, the newly identified splicing factors ESRP1 and ESRP2 have
been also shown to be downregulated by transcription repressors
Twist, Snail, and ZEB (71). Additionally, complex alterations in
various splicing factors may mediate the increased IR-A:IR-B ratio
during EMT. Although incompletely known, these alterations may
involve increased hnRNP A1 expression and reduced hnRNP F and
SF2/ASF (72). Interestingly, activation of the EGFR/ERK path-
way was associated with increased IR-A:IR-B and dysregulation of
several splicing factors, including CUGBP1, hnRNPH, hnRNPA1,
hnRNPA2B1, and SF2/ASF, involved in IR gene splicing (73).
CROSS-TALK OF IGF SIGNALING WITH TRANSCRIPTION
FACTORS AND PATHWAYS INVOLVED IN NORMAL AND
CANCER STEM CELL BIOLOGY
From the seminal paper of Takahashi et al. (74), we have learnt that
adult dermal fibroblasts could be reprogramed to acquire pluripo-
tency, a key property of stem cells, with a combination of only four
transcription factors (Oct-3/4, SOX2, Klf-4, and c-Myc). An addi-
tional transcription factor, Nanog was required in the final stages
of cell reprograming. However, there is some flexibility in tran-
scription factors required for cell reprograming. For instance, Myc
is not absolutely required, and a different transcription factor com-
bination (Oct-4, SOX2, Lin28, and Nanog) can work equally well
(75). Cell reprograming is more efficient when p53 is inactivated
(76), indicating that p53 plays also a key role in the regulation of
stemness. For instance, p53 directly down-regulates pluripotency
genes, such as Oct-4 and Nanog (77, 78). In turn, Nanog, by upreg-
ulating FAK, a negative regulator of p53 transcriptional activity,
represses p53 expression (79). In accordance with these findings,
p53 mutant forms have been found to induce EMT activators
(ZEB1, ZEB2, Slug, and Snail) and stem cell expansion (80, 81).
Moreover, stem cell ability to self-renew and differentiate into
specialized lineages is regulated by microenvironmental signals
present in the stem cell niche. These signals include those belong-
ing to the pathways of Wnt, Notch, Sonic hedgehog (Shh), SAT3/5,
TBFβ, and others, which acts individually or by integrating with
other signals (82, 83). Several of these pathways are frequently dys-
regulated in cancer and may play crucial roles in stem-like cancer
cells.
Intriguingly, the IGF system is linked to these transcrip-
tion factors and signaling pathways by a complex network of
interactions.
CROSS-TALK WITH PLURIPOTENCY TRANSCRIPTION FACTORS
One link between IGF signaling and pluripotency factors is rep-
resented by p53, which is a common negative regulator of IGF-IR
(see next paragraph),and of Oct-4 and Nanog (78). In turn, IGF-IR
signaling induces p53 phosphorylation and inactivation (84), thus
relieving p53 suppression on Oct-4 and Nanog. Another link is
represented by hypoxia factors 1 and 2 (HIF-1 and HIF-2), which
orchestrate the up-regulation of several factors involved in cell
transformation, EMT, and pluripotency, including Twist, Snail,
Oct-4, SOX2, and Nanog (85). Besides being activated by hypoxia,
HIFs are also activated by several growth factors, including IGFs
(86) through the PI3K/Akt/mTOR pathway (87).
Moreover, IGF-IR may modulate the expression and func-
tion of pluripotency factors through the cross-talk with the
Wnt/β-catenin pathway (see Section Cross-Talk with Wnt/β-
Catenin Signaling). In particular, it has been shown that the
IGF-IR/PI3K/GSK3β pathway mediates Oct-4 up-regulation as
well as the formation of β-catenin/Oct-4/SOX2 complex, which
is able to activate the Nanog promoter and maintain self-renewal
of lung cancer stem-like cells (26). These data fit well with findings
obtained in human hepatocarcinoma. In this malignancy, Nanog
expression correlates with poor prognosis. Moreover, Nanog+ cell
populations showed the hallmarks of stemness, which were depen-
dent on the presence of a functional IGF-IR. Nanog+ cells were
characterized by increased transcription of several components
of the IGF system (IGF-II, IGF-BP2, and IGF-BP5) and by the
up-regulation of IGF-II and IGF-IR proteins. Nanog knockdown
reduced IGF-IR levels, while, in turn, IGF-IR blockade inhibited
Nanog expression, suggesting a positive feed-back loop between
Nanog function and IGF-IR signaling (24).
CROSS-TALK WITH p53, Sp1, AND HMGA1 PROTEINS
The IGF-IR promoter region contains multiple GC boxes, poten-
tial binding sites for Sp1, a transcription factor involved in IGF-IR
promoter constitutive activity. p53, as well as Wilms’ tumor-
suppressor 1, Breast Cancer 1, and other anti-oncogenes negatively
regulate IGF-IR transcription, partially through functional inter-
action with Sp1 (88). p53 controls IGF-IR expression also at post-
transcriptional level through Mdm-2. When p53 is inhibited and
Mdm-2 overexpressed, Mdm-2 is redistributed from p53 to IGF-IR
and this mechanism results in IGF-IR ubiquitination and degrada-
tion (89). Although less studied, IR promoter is also repressed by
wild type p53 (90). These findings help explaining why the reduced
activity of these anti-oncogenes may be associated with IR and
IGF-IR up-regulation. Additionally, the functional link between
p53 and high motility group A1 (HMGA1) proteins may play an
important role in IR and IGF-IR up-regulation in CSCs.
High motility group A1 proteins are chromatin architectural
factors acting as both positive and negative regulators of gene
transcription. In normal cells, HMGA1 expression is restricted to
embryogenesis while in transformed cells it is present at high lev-
els and correlates with an aggressive behavior (91). Similarly to
p53, also HMGA1 proteins cooperate with other signaling path-
ways to sustain stemness features, EMT process, and metastatic
properties. Indeed, in breast and colon cancer HMGA-depleted
cells,β-catenin was relocated from the nucleus to cell–cell contacts
and mesenchymal marker vimentin and the Notch pathway, were
downregulated. Concomitantly, HMGA1 depletion was associated
with reduction in sphere self-renewal, dimension, and growth.
Yet, HMGA1 was also seen to be associated with a gene signa-
ture containing genes important for EMT, stemness, metastasis,
pluripotency, and strictly linked to the Wnt/β-catenin, Notch and
Pin1/mutant p53 signaling pathways (92, 93).
Some of HMGA1 effects may be mediated by the IR/IGF-IR
system. In fact, HMGA1 is able to relieve the inhibitory control
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FIGURE 2 | Schematic representation of the relevant functional
interactions occurring between p53 and HMGA1 proteins, the IGF
system and other factors involved in pluripotency and EMT. p53
represses the promoter activity of IR and IGF-IR and regulates both
receptors also at post-transcriptional levels through the induction of
Mdm-2. Mdm-2, in turn, is redistributed from p53 to IGF-IR and induces its
degradation. In addition, p53 down-regulates signals important for
pluripotency (Oct-4, Nanog) and stemness maintenance (Wnt, Notch,
Shh). Some of these signals, in turn, modulate p53 functions. For example,
Nanog inhibits p53 tumor-suppressor activity through FAK up-regulation.
HMGA1 proteins, by impairing the regulatory activity of p53, but also by
direct binding to promoter sequences and by stabilizing transcriptional
complexes, upregulate IR and IGF-IR as well as transcriptional factors and
signaling pathways linked to stemness.
of p53 on IR and IGF-IR gene transcription by interacting with
the oligomerization domain of p53 and inhibiting p53 ability to
oligomerize into functionally active tetramers (94). Additional
mechanisms, by which HMGA1 may activate IR and IGF-IR
transcription include direct interaction with the IR and IGF-
IR promoter, and stabilization of transcriptional multiprotein
complexes and protein–DNA interactions, including enhance-
ment of Sp1 effect on the IR and IGF-IR promoters (95–97). A
schematic representation of some of these interactions is given in
Figure 2.
Therefore, tumors with inactivating mutations of p53 and/or
overexpression of HMGA1 are often poorly differentiated and
characterized by increased IR and IGF-IR up-regulation (91, 98).
CROSS-TALK WITH Wnt/β-CATENIN SIGNALING
The canonical Wnt signaling is initiated when a Wnt lig-
and engages co-receptors of the Frizzled (Fzd) and low-density
lipoprotein receptor related protein (LRP) families. In the absence
of Wnt, β-catenin is part of a multiprotein complex including
axin, the adenomatous polyposis coli protein (APC) and GSK3β.
As previously mentioned, GSK3β is a constitutively active kinase,
which phosphorylates specific Ser and Thr residues of β-catenin,
prompting β-catenin proteasomal degradation. Wnt binding to its
co-receptors induces phosphorylation and inactivation of GSK3β,
with consequent β-catenin stabilization, and translocation into
the nucleus where it binds TCF/LEF (T cell factor/lymphoid-
enhancer binding factor) transcription factor, a key activator of
the expression of target genes controlling cell fate and self-renewal
of stem/progenitors during development and specification in a
variety of tissues (99–101). In particular, this pathway activated
the expression of Oct-4 and Nanog, crucial regulators of cell
pluripotency (102).
The tightly regulated activation of Wnt/β-catenin signaling, as
well as β-catenin expression and localization may be subverted in
a variety of human cancers, thus inducing an imbalance between
long-term renewal and differentiation program (12, 101), which
favors CSCs expansion (100). For example, in hematopoietic stem
cells, Wnt activity is required for self-renewal, for the transforma-
tion of progenitor cells by certain oncogenes, and for acquiring
drug-resistance (103, 104). Furthermore, the suppression of β-
catenin completely abolished the development of mixed lineage
leukemia stem cells, reversed leukemia stem cells to a pre-leukemia
stem-like stage, and induced a greater responsiveness to GSK3β
inhibitors in vivo and in vitro (105). Wnt/β-catenin signaling has
also emerged as an essential pathway for self-renewal of intesti-
nal stem cells and for their malignant transformation. Indeed,
the apc gene, encoding the APC protein, is silenced in over 80%
of human colon cancer (106). Loss of APC function and acti-
vating mutations of β-catenin are early steps in the pathogenesis
of colorectal cancer (107). Colon CSCs are functionally charac-
terized by high Wnt signaling activity, while the differentiated
progeny of these cells own markedly lower levels of Wnt acti-
vation (108). This gradient in Wnt signaling activity is partially
dependent on the microenvironment, the so-called CSC niche.
Environmental factors, like hepatocyte growth factor (HGF) pro-
duced by stromal myofibroblasts, activate β-catenin-dependent
transcription and subsequently CSC clonogenicity. More signif-
icantly, these stromal factors also induce the CSC phenotype in
more differentiated tumor cells (109). In mammary gland, Wnt
is necessary for the regulation of self-renewal and differentiation
of mammary stem cells (MSCs) during embryogenesis and preg-
nancy in adult life. Although mutations in components of the
Wnt pathway have not been identified in human breast cancers, in
over 50% of them, this pathway is constitutively stabilized (110).
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FIGURE 3 | Schematic representation of the interplay between the
canonicalWnt/β-catenin pathway and IGF signaling. The activation of
the canonical Wnt/β-catenin pathway is triggered by the binding of Wnt
ligands to FZD (frizzled) and LRP (LDL-related receptor protein) receptors on
target cells. Receptor occupancy inhibits the kinase activity of the
destruction complex, consisting of APC (adenomatous polyposis coli), Axin,
Dsh (Disheveled), and GSK3β. As a consequence, β-catenin is uncoupled
from the degradation complex and accumulates and translocates into the
nucleus, where it binds LEF/TCF transcription factors. These events trigger
efficient transcription of genes that are important regulators of cell
proliferation, cell cycle progression, and stem cell fate. Wnt target genes
include IRS-1, which, in turn, amplifies the IGF-IR/PI3K pathway and its
mitogenic signals. IRS-1 contributes to β-catenin stabilization by activating
PI3K pathway and inducing GSK3β inhibition. Furthermore, after IGF-I
stimulation, IRS-1 partially translocates into the nucleus where it binds to
and co-localizes with β-catenin, further contributing to TCF dependent
transcription. β-catenin also exists in a cadherin-bound form and regulates
cell–cell adhesion.
Aberrant activation of Wnt/β-catenin signaling induces tumors
of undifferentiated basal cells, while β-catenin inhibition in the
mouse mammary gland blocks organ development, pregnancy-
induced proliferation, and reduces the number of alveolar progen-
itor cells (111). Yet, Wnt/β-catenin activation has also been linked
to radio- and chemo-resistance of mammary tumor-initiating
cells (112).
Several lines of evidence demonstrate that a strict cooperation
between the Wnt/β-catenin and IGF signaling may contribute to
carcinogenesis and cancer progression (see Figure 3). In human
colon cancer cells, IGF-I stimulates tyrosine phosphorylation of
β-catenin and of IRS-1 and E-cadherin, two β-catenin interacting
proteins. This results in the disruption of β-catenin – E-cadherin
interaction, and increased cell motility. Chiefly, IGF-I stimulates β-
catenin relocation and stability through the inactivation of GSK3β
(113), thus contributing to colon cell proliferation (114). Through
the same pathway, IR and IGF-IR may also stimulate Oct-4 and
Nanog expression. Indeed, IGF-IR was required for Oct-4 to form a
complex with β-catenin and SOX2, which then activates the Nanog
promoter (26).
Because IGF-IR is overexpressed in the proliferating cells at the
base of the colonic crypts, which could be considered the colon
tumor-initiating cells (115), and Wnt/β-catenin signaling plays
a critical role in stimulating colonocyte proliferation (116), it is
possible that the interplay between these two pathways could con-
tribute to the expansion of colon tumor-initiating cells pool. This
hypothesis, although requiring further validation, could be applied
to other cancer models where both cascades are deregulated.
This could be also the case of hepatocellular carcinoma, where
insulin and IGF-I cooperate with Wnt signaling in the carcino-
genesis process by stimulating TCF/LEF dependent transcription
through the PI3K/GSK3β/β-catenin pathway (117). Evidence in
oligodendroglial cultures cells supports the notion that β-catenin
may mediate IGF-I actions on cyclin D1 expression, cell prolif-
eration, and survival (118). All these mechanisms have also been
demonstrated in cultured precursor/stem cells, where they may
contribute to trigger the early steps of the carcinogenesis process
(118, 119). Likewise IGF-I, IGF-II is also able to induce β-catenin
relocation to the nucleus and the transcription of β-catenin/TCF-
3 target genes. In parallel with these molecular events, IGF-II
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triggers intracellular sequestration and degradation of E-cadherin
inducing rapid EMT (120).
The effect of IGF-I on β-catenin localization and stabilization
is also affected by IRS-1. After IGF-I stimulation, IRS-1 is par-
tially translocated to the nucleus, where it binds and co-localizes
with β-catenin (121). On the other hand, IRS-1 itself is a down-
stream target gene of β-catenin, which regulates IRS-1 expression
in vivo. The interplay between IRS-1 and β-catenin may repre-
sent another mechanism promoting cancer initiation (122), and
regulating self-renewal and differentiation processes (123). Taken
together, these data highlight the existence of a close connection
and a positive feed-back loop between the Wnt/β-catenin and IGF
signaling, which contribute to oncogenesis and EMT process.
CROSS-TALK WITH NOTCH SIGNALING
The Notch system consists of four transmembrane isoform recep-
tors (Notch-1, Notch-2, Notch-3, and Notch-4) and five canonical
transmembrane ligands [Delta-like (DLL)-1, DLL-2, DLL-3, DLL-
4, Jagged-1, and Jagged-2]. Notch receptor activation requires
cell-to-cell interaction and starts after binding to a ligand pre-
sented by a neighboring cell. This event triggers three consecutive
proteolytic cleavages, including a final cleavage by a γ-secretase
complex, which produces an active and stable Notch fragment
(Notch intracellular or NIC). NIC then translocates to the nucleus
and binds to the DNA-binding protein CSL (CBF-1-Suppressor
of Hairless/Lag1), a constitutive transcriptional repressor, which
displaces other co-repressors and recruits additional co-activators
to induce the transcription of genes involved in differentiation,
survival, self-renewal, and cell fate.
It is now well known that Notch pathway is aberrantly activated
in a variety of tumors (124, 125). Accumulating evidence supports
the involvement of the Notch pathway in CSC biology, tumor
metastasis, angiogenesis, antitumor treatment resistance and EMT
process. In particular, Notch signaling induces morphological
changes shared by EMT and stem-like signatures, involving down-
regulation of endothelial and epithelial markers (VE-cadherin,
Tie1, Tie2, endothelial NO synthase, etc.), up-regulation of mes-
enchymal markers (A-SMA, fibronectin, N-cadherin, Vimentin,
PDGF, ZEB1, Twist, Snail, Slug), and increased expression of stem-
like markers [Oct-4, SOX2, Nanog, Lin28B; Ref. (126–128)]. Con-
versely, reduction of Notch signaling is associated with reduced
proliferation, increased apoptotic susceptibility, reduced tumor-
sphere formation, prevention of in vivo tumor implantation, and
changes in the expression of stemness transcription factors [Oct-4,
SOX2, Nanog; Ref. (129–132)]. Moreover, several studies have
shown that only the cell subpopulation characterized by Notch
activity/overexpression has the ability to form spheres in vitro, to
self-renew, and to resist to chemotherapy (131, 133, 134).
For the aforementioned reasons, Notch has become an attrac-
tive therapeutic target to reverse EMT-dependent maintenance of
CSCs, chemo-resistance, and tumor spread in several malignancies
characterized by Notch pathway deregulation (110, 125).
The interaction between the Notch and the IGF-IR pathway has
been firstly demonstrated by Eliasz et al. in lung adenocarcinoma
cells (135). In these cells, under hypoxic conditions, Notch-1 stim-
ulates IGF-IR transcription by regulating its promoter. Notch-1
seems to act directly, because Notch-1 downstream targets failed
to modify IGF-IR expression (135). This regulatory mechanism
of IGF-IR by Notch-1 is evolutionary conserved. In Drosophila,
Notch-1 and insulin/IGF signals are required to control the num-
ber of the cap cells of the niche and to promote germ-line stem
cell division (136). In Caenorhabiditis elegans, both pathways are
intrinsically essential for surviving under unfavorable conditions
such as hypoxia (137). The Notch-mediated IGF-IR regulation in
hypoxic environment is important also in cancer stem biology.
Indeed, hypoxia, through HIF-1α, usually promotes stem-like fea-
tures providing a niche for tumor-initiating cells. These cells in
hypoxic tumor areas are often dependent for growth and survival
by Notch; they are also highly resistant to apoptosis and to angio-
genesis inhibitors. Thus, it is possible that these tumor-initiating
cells require the activation of HIF-1α/Notch/IGF-IR/Akt path-
way, and may become sensitive to the antitumor effect of Notch
inhibitors in combination with IGF-IR/Akt inhibitors.
The link between Notch and IGF-IR signaling has recently been
confirmed in human T lymphoblastic leukemia (T-ALL) initiating
cells (32), where IGF-IR was recognized as a Notch-1 target, as
Notch directly up-regulated IGF-IR protein and mRNA expression
in all cell lines analyzed. Notch inhibition resulted in only two- to
three-folds decrease in IGF-IR expression, suggesting that Notch is
not the only factor affecting IGF-IR up-regulation and signaling.
However, Notch induced IGF-IR overexpression was sufficient to
robustly enhance the sensitivity of T-ALL cells to IGF-I/II.
This cross-talk with Notch may represent a general mechanism
through which IGF-IR signaling influences the growth, the main-
tenance, and the activity of tumor-initiating cells with self-renewal
capacity. A schematic representation between Notch and IGF-IR
pathways is shown in Figure 4.
CROSS-TALK WITH Shh SIGNALING
The Shh pathway has been extensively studied for its critical role
in regulating proliferation, cell fate, patterning, developmental,
and cancer biology (138). During embryonic development, Shh
controls pattern formation and modulates the proliferation and
differentiation of progenitor/stem cells. In the adult, Shh regulates
cell homeostasis through the selective activation of transcription
factors involved in the maintenance of stem cells, tissue repair,
and regeneration (139). Shh signaling is activated by Shh glyco-
protein which binds the transmembrane receptor Patched (PTCH)
to release the seven-transmembrane smoothened (SMO) protein
from PTCH repression (138). SMO, in turn, activates STK36 ser-
ine/threonine kinase and stabilizes GLI family transcription fac-
tors (GLI1, GLI2, GLI3), which activate the transcription of GLI
targets genes, including cyclin D1, Bcl-2, osteopontin, PTCH1,
FOXL1, and JAG2. Several evidences have shown that the Shh
pathway is often deregulated in various types of solid and non-
solid tumors. Mutations in key components of Shh pathway, such
as Patch1 and SMO, have been found in tumors from differ-
ent tissues/organs, including brain, skin, pancreas, colon, lung,
and prostate (140–143). Moreover, activation of Shh signaling
plays a role in various steps of oncogenesis, from cancer ini-
tiation to progression and metastasis. During cancer initiation,
Shh/GLI dependent gene transcription regulates stemness and
self-renewal, as revealed by the up-regulation of specific CSC
markers such as BMI1, CD133, and CD44 (139). During tumor
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FIGURE 4 | Schematic representation of the cross-talks between the
Notch and the IGF signaling. The Notch receptor is activated by the
binding to ligands (Delta-like 1/3/4; Jagged-1/2) presented by a neighboring
cell. Notch activation requires three consecutive proteolytic cleavages. The
final cleavage is mediated by a γ-secretase complex, which releases an
active fragment (Notch-IC). Notch-IC, then, translocates into the nucleus
where it interacts with the DNA-binding protein CSL (suppressor of
Hairless), a constitutive transcription repressor. Upon Notch-IC binding,
CSL undergoes allosteric modifications, which displace co-repressors and
recruit co-activators (CoAs) to activate transcription. Notch dependent
signaling induces several genes associated with differentiation, survival,
stemness, and EMT. Notch target genes include Hes and Hey family of
basic helix-loop-helix transcription factors, D-cyclins, transcription and
growth factors relevant to EMT and to IGF-IR/PI3K pathway. Notch
signaling is often and aberrantly activated by hypoxia through HIF-1-α.
Under hypoxic conditions, Notch-1 stimulates IGF-IR transcription by
regulating its promoter and amplifying the mitogenic effects mediated by
IGF-IR/PI3K signaling.
growth, to fuel cancer cells, Shh pathway regulates key genes
involved in cell proliferation, cell cycle progression, apoptosis, and
survival (i.e., Bcl-2, TRAIL, cyclins, and c-myc) (139). Shh also
contributes to cancer progression and metastasis by favoring the
EMT transition through the up-regulation of Snail and the down-
regulation of E-cadherin (144), thus contributing to re-program
cancer cells toward a stem-like phenotype. Particular attention has
been recently focused on the role of Shh pathway in the control of
brain tumor stem-like cells (BTSCs), and in the genesis of brain
tumors. It has been observed that GLI1 is expressed in the germi-
native zones of the brain, where Shh maintains a proliferative state
(145), and in a variety of brain tumors including medulloblas-
tomas of the cerebellum and gliomas of the cerebral cortex (146).
In cerebellar granule precursors, which are believed to be the cells
of origin for medulloblastoma, Shh signaling constitutive activa-
tion results in significantly ectopic expression of SOX2. Therefore,
through SOX2 induction, Shh drives medulloblastomas cellular
growth and proliferation (147). Similarly, in neural stem cells in the
central nervous system, SOX2 gene is regulated by the downstream
mediator of Shh signaling, GLI2 transcription factor, to sustain
neural stem cells growth, expansion, and to prevent neuronal dif-
ferentiation (148). In a subset of gliomas, gene-expression profile
has recently confirmed the activation of Shh signaling and its key
role in controlling glioma CSC self-renewal, growth, and survival.
Interestingly, interference of Shh signaling with cyclopamine, a
specific SMO inhibitor, or through lentiviral-mediated silencing,
decreased glioma stem cell proliferation and CSC-initiated brain
tumor formation in mice further confirming the important role
of this pathway in controlling the behavior of BTSCs (149).
Using a RCAS/tv, a system, which allows a cell type specific
postnatal gene transfer, Rao et al. have shown that Shh and IGF sig-
naling synergize to induce medulloblastomas in mice (150). They
found that the rate of Shh-induced tumor formation increases
from 15 to 39%,when IGF-II is coexpressed,whereas no tumor for-
mation was seen in mice injected with IGF-II alone. Furthermore,
the induced tumors showed up-regulation of IRS-1 and phospho-
rylated IGF-IR, indicating a sustained activation of IGF signaling
in these tumors. Other research groups have also reported coop-
eration between Shh/Ptch signaling and IGF system. In particular,
it appears that IGF-II is essential for Shh-mediated medulloblas-
toma and rhabdomyosarcoma formation in Ptch mutant mice,
and that IGF-II is a downstream transcriptional target of Shh,
suggesting that IGF-II acts as a critical mediator of Shh func-
tion (151). Similarly, in cerebellar granule precursors, both IGF-I
and IGF-II have synergistic proliferative effects with exogenous
Shh, as Shh-induced proliferation is dependent on IGF-IR func-
tion (152). Synergism between Shh and IGF signaling has also
been seen in glioma stem cells (153, 154), where Shh/GLI sig-
naling regulates IGF dependent malignant behavior by increasing
IRS-1 transcription. Indeed, genetic or pharmacological inhibition
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FIGURE 5 | Proposed model for the interaction between Shh and IGF
signaling. Shh binds to patched family receptors (PTCH) to releases
smoothened (SMO) signal transducer from Patched-dependent
suppression. Activated SMO, in turn, induces SKT36 serine/threonine
kinase to stabilize GLI family members for nuclear translocation. Shh
signaling activates GLI dependent transcription of target genes including
N-myc, D-cyclins, BMI1, GLI1, Bcl-2, and IRS-1, all of which have been
implicated in cell cycle progression, proliferation, and stemness. IRS-1, in
turn, mediates IGF-IR/PI3K signaling activation, which inhibits
GSK3β-mediated phosphorylation and consequent increased degradation of
N-myc and D-cyclins. However, Shh may also activate IGF-IR/PI3K pathway
via unknown intermediary molecules.
of GLI1 decreases IGF-I induced glioma stem cells self-renewal,
proliferation, migration, angiogenesis, and IGF dependent MAPK
activation. In addition, the blockade of Shh/GLI1 and IGF path-
ways sensitizes glioma stem cells to the chemotherapeutic agent
temozolomide. Findings in cerebellar neural precursors are also
consistent with the observation that Shh uses components of the
IGF pathway to drive proliferation (155). In these cells, Shh upreg-
ulates IRS-1 by interfering with mTOR-mediated IRS-1 degrada-
tion, and by enhancing IRS-1 translation. Shh, therefore, through
the newly translated and stabilized IRS-1, enhances IGF mediated
survival and mitogenesis. However, this mechanism of pathway
cooperation is not exclusive and there may be multiple sites and
modes of interaction between Shh and IGF system. For exam-
ple, IGF-IR activation enhances Shh signaling by inhibiting the
GSK3β and the consequent degradation of N-myc and cyclin D1,
both of which are critical mediators of the Shh pathway (156,
157). Alternatively, IGF and Shh signaling could also interact at
the level of GLI1 regulation, upstream of N-myc and cyclin D1
(158), or through other components of the IGF system, such as
the IGF-BPs (152). The synergistic interaction between Shh and
IGF signaling is not linear and could be mediated by not yet fully
known intermediary molecules. A scheme depicting the interplay
between Shh and the IGF system is shown in Figure 5. Collectively,
these results, although obtained in neural cells and still needing
validation in other organs, provide strong evidence that Shh/GLI
signaling synergizes with the IGF system.
CONCLUSION AND PERSPECTIVES
It is well established that IGF signaling plays a crucial role in cancer,
and that both several oncogenes and anti-oncogenes regulates IGF-
IR expression and signaling to sustain cancer progression (159).
This notion has stimulated the development of IGF-IR blocking
therapies, with the aim to block cancer growth with minimal side
effects on glucose metabolism. However, IGF-IR overexpression
is only part of the complex IGF signaling deregulation occurring
in cancer, and it has soon become evident that overactivation of
other components of the IGF system, including the IGF-II/IR-A
circuitry and systemic hyperinsulinemia, may induce resistance to
IGF-IR blocking therapies (9, 65). The disappointing results of
clinical trials with anti-IGF-IR antibodies have not disproved that
the IGF signaling plays a key role in cancer but have clearly indi-
cated that this system is a difficult one to target because of the
several levels of homeostatic control.
Noteworthy, several recent studies now support the concept
that IGF signaling not only plays a proliferative and antiapoptotic
role in cancer cells, but also sustains cancer cell EMT and stemness,
two key features of cancer cell renewal and metastatic phenotype.
In fact, on one hand, the IGF signaling appears to stimulate the
transcription factors of the ZEB and the Snail family implicated
in the EMT program, and, on the other hand, it strictly interacts
with transcription factors (e.g., Oct-4, SOX2, Nanog, p53, HMGA1
proteins) and specific signaling pathways (the Wnt/β-catenin, the
Notch, and the Shh pathways) classically involved in cell stemness.
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These interactions occur through several components and multi-
ple modalities, establishing an intricate network characterized by
multiple positive feed-back mechanisms. These findings may open
new hope for cancer treatment, by showing that targeting the IGF
system is still a viable option in several malignancies, but we need
to target at the same time other components of this complex sig-
naling network especially cooperating in the EMT process and cell
stemness.
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